7 stories mentioning SHA:600566Updated 44d ago
Every FINWIRES story that references SHA:600566, newest first.
Hubei Jumpcan Pharmaceutical (SHA:600566) obtained drug registrations from China's medical products regulator for pediatric laxative and mesalazine sustained-release granules.Pediatric laxative granules are used to relieve constipation in children, while mesalazine is used to treat mild to moderate ulcerative colitis and Crohn's disease, according to a Monday filing with the Shanghai bourse.
Chinese authorities included Hubei Jumpcan Pharmaceutical (SHA:600566) subsidiary Jumpcan Pharmaceutical's fermented soybean and forsythia clearing-heat granules for children in the country's essential medicines list, according to a Friday filing with the Shanghai bourse.The granules help treat childhood wind-heat colds with stagnation syndrome, the company said in its filing.Sales of the drug reached 264.1 million yuan in the first quarter.
Hubei Jumpcan Pharmaceutical (SHA:600566) obtained a drug registration certificate for marboxil tablets, according to a Shanghai bourse filing on Tuesday.The certificate was received through subsidiary Jichuan Pharmaceutical Group and Zenshine Pharmaceutical (Nanjing) Group.The drug is used for the treatment of uncomplicated influenza A and B in adolescents aged 12 years and older.
Hubei Jumpcan Pharmaceutical (SHA:600566) said China's drug regulator granted Pudilan Xiaoyan oral liquid the status of nationally protected traditional Chinese medicine.The drug is used to treat upper respiratory infections, according to a Monday filing with the Shanghai bourse.The protection period is seven years from the announcement date.Shares of the pharmaceutical company were down 2% in recent trade.
Hubei Jumpcan Pharmaceutical's (SHA:600566) Jianwei Xiaoshi Oral Liquid was selected for the National Chinese Patent Medicine's centralized procurement, according to a Friday disclosure to the Shanghai bourse.The drug is used to treat food stagnation and indigestion.During the procurement period, medical institutions will prioritize the use of the selected products, the pharmaceutical company said.
Hubei Jumpcan Pharmaceutical's (SHA:600566) attributable profit fell 9.1% to 400.1 million yuan in the first quarter from 440.3 million yuan in the year-ago period, according to a Friday filing with the Shanghai bourse.Earnings per share at the drug manufacturer decreased 8.3% to 0.44 yuan from 0.48 yuan in the prior-year period.Operating income declined 21% year over year to 1.21 billion yuan from 1.53 billion yuan.
Hubei Jumpcan Pharmaceutical's (SHA:600566) net profit attributable to shareholders in 2025 dropped 30% year on year to 1.78 billion yuan, or 1.93 yuan per share, according to a Shanghai bourse filing on Friday.Operating revenue fell 22% to 6.22 billion yuan from 8.02 billion yuan in the prior year.
